Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience
Journal of Clinical Medicine · 05.12.2023 · 12 (24) · 7503
DOI: 10.3390/jcm12247503 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 05.12.2023. Verfasst von Silvia Giordano und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Clinic, Medical Sciences Department, University of Turin, 10121 Torino, Italy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Interleukin 23 (IL-23) inhibitors, such as guselkumab, risankziumab, and tildrakizumab, have proved to be highly effective and safe for psoriasis treatment either in bio-naïve or bio-experienced patients. A substantial proportion of patients show a primary or secondary inefficacy to IL-17 inhibitors and can benefit from an alternative line of treatment, like IL-23 inhibitors. To date, no sufficient data are available on the effectiveness of IL-23 inhibitors after an anti-IL-17 agent.
Methods
Our study includes 48 patients with moderate to severe psoriasis undergoing a switch from IL-17 to IL-23 inhibitors. This trial is registered with SS_DERMO_20.
Results
The mean PASI (Psoriasis Area Severity Index) decreases from 11.6 to 3.3 at week 16, with responses maintained at weeks 28 and 52 (2 and 1.4, respectively), and a PASI100 achievement in more than 24% of patients at 16 weeks and 61.9 at 48 weeks, with no occurrence of serious adverse events. However, almost one in six patients interrupted the IL-23 inhibitors mainly due to primary ineffectivenss.
Conclusions
Our data support the evidence that an interclass switch among IL-17 inhibitors is a safe and effective therapeutic option for these patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dermatology Clinic, Medical Sciences Department, University of Turin, 10121 Torino, Italy.
ORCID-Profile: Simone Ribero, Luca Mastorino
Zitieren
APA
Giordano, S., Dapavo, P., Ortoncelli, M., Stroppiana, E., Verrone, A., Quaglino, P., Ribero, S., & Mastorino, L. (2023). Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience. Journal of Clinical Medicine, 12(24), 7503. https://doi.org/10.3390/jcm12247503
Vancouver
Giordano S, Dapavo P, Ortoncelli M, Stroppiana E, Verrone A, Quaglino P, et al. Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience. Journal of Clinical Medicine. 2023;12(24):7503. doi:10.3390/jcm12247503
BibTeX
@article{Giordano2023,
author = {Giordano, Silvia and Dapavo, Paolo and Ortoncelli, Michela and Stroppiana, Elena and Verrone, Anna and Quaglino, Pietro and Ribero, Simone and Mastorino, Luca},
title = {Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {24},
pages = {7503},
doi = {10.3390/jcm12247503}
}
EUVIMED